7-iodo-4-naphthalen-1-ylmethyl-3-(4-trifluoromethoxy-phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione | 787633-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 7-iodo-4-naphthalen-1-ylmethyl-3-(4-trifluoromethoxy-phenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione
• 英文别名: 7-Iodo-4-(naphthalen-1-ylmethyl)-3-[4-(trifluoromethoxy)phenyl]-1,3-dihydro-1,4-benzodiazepine-2,5-dione
• CAS: 787633-55-0
• 化学式: C₂₇H₁₈F₃IN₂O₃
• 分子量: 602.351
• InChiKey: HMDQKBMMWVNRHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Substituted 1,4-diazepines and uses thereof
  申请人：——

  公开号：US20040220179A1

  公开（公告）日：2004-11-04

  The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R 1 , R 2 , R 9 , R 10 , R a , R d and M are defined herein; X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; and R 3 is —CO 2 R d , —CO 2 M, —OH, —NHR d , —SO 2 R d , —NHCONHR d , optionally-substituted amidino or optionally-substituted guanidino; or R 3 —X— is hydrogen or an electron pair; R 4 is oxygen or —NR 9 R 10 ; R 5 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; and R 6 , R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R 6 and R 7 , together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with R a .

  本发明涉及新型1,4-二氮杂环烷化合物，其药物组成物，以及其作为HDM2-p53相互作用抑制剂的用途。化合物具有以下结构式I：1或其溶剂化合物、水合物或药用可接受盐；其中：R1、R2、R9、R10、Ra、Rd和M在此处定义；X是以下结构的双价基团：烷烃、环烷烃、可选取代芳烃、可选取代杂芳烃、可选取代芳基烷烃或可选取代杂芳基烷烃；而R3为—CO2Rd、—CO2M、—OH、—NHRd、—SO2Rd、—NHCONHRd、可选取代酰胺基或可选取代胍基；或者R3—X—为氢或电子对；R4为氧或—NR9R10；R5为环烷基、芳基、杂芳基、环烷基烷基、芳基烷基、杂芳基烷基，或饱和或部分不饱和的杂环，每种均可选取代；而R6、R7和R8独立地为氢、烷基、环烷基、芳基、杂芳基、饱和或部分不饱和的杂环、环烷基烷基、芳基烷基、杂芳基烷基，每种均可选取代；或者R6和R7，与它们相连的碳原子共同形成一个3至7成员的碳环，可选取代1至3次以Ra。
• Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
  申请人：Lu Tianbao

  公开号：US20050227932A1

  公开（公告）日：2005-10-13

  The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.

  本发明针对治疗癌症或其他细胞增殖性疾病提供了一种联合治疗方案。这种治疗方案将放射治疗或化疗与使用MDM2：p53相互作用的小分子抑制剂相结合。
• Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1712235A2

  公开（公告）日：2006-10-18

  The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.

  本发明涉及一种治疗癌症或其他细胞增殖性疾病的组合疗法。这种疗法将放疗或化疗与 MDM2：p53 相互作用的小分子抑制剂结合使用。
• EP1617807A4
  申请人：——

  公开号：EP1617807A4

  公开（公告）日：2007-02-21
• EP1617807A2
  申请人：——

  公开号：EP1617807A2

  公开（公告）日：2006-01-25